Current Gastroenterology Reports

, Volume 5, Issue 1, pp 48–56 | Cite as

Treatment of hepatic fibrosis: Almost there

  • Efsevia Albanis
  • Rifaat Safadi
  • Scott L. Friedman


Hepatic fibrosis is the scarring response of the liver to chronic liver injury; when fibrosis progresses to cirrhosis, morbid complications can develop. Available therapies for many chronic liver diseases are ineffective, with liver transplantation as the only option, though the supply of donor organs is inadequate to meet the growing demand. Novel approaches that attack the scarring response are therefore urgently needed. Optimism in this effort is fueled by major insights into the pathogenesis of fibrosis and by accumulating evidence that even cirrhosis is reversible in many patients. Most evolving antifibrotic therapies will be aimed at inhibiting the activated hepatic stellate cell, which is responsible for the fibrotic response to injury. This review describes the ways in which insights into the cellular basis of hepatic fibrosis are leading to realistic strategies for antifibrotic treatment that may revolutionize the management of patients with chronic liver disease.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Friedman SL: Molecular regulation of hepatic fibrosis: an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247–2250. This review outlines current concepts about molecular events underlying activation of hepatic stellate cells during liver injury.PubMedCrossRefGoogle Scholar
  2. 2.
    Friedman SL, Maher JJ, Bissell DM: Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 2000, 32:1403–1408.PubMedCrossRefGoogle Scholar
  3. 3.
    Pinzani M, Marra F: Cytokine receptors and signaling during stellate cell activation. Semin Liver Dis 2001, 21:397–416.PubMedCrossRefGoogle Scholar
  4. 4.
    Bachem MG, Schneider E, Gross H, et al.: Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998, 115:421–432.PubMedCrossRefGoogle Scholar
  5. 5.
    Iredale JP: Stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001, 21:427–436.PubMedCrossRefGoogle Scholar
  6. 6.
    Wong L, Yamasaki G, Johnson RJ, Friedman SL: Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994, 94:1563–1569.PubMedGoogle Scholar
  7. 7.
    Rockey DC: Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001, 21:337–350.PubMedCrossRefGoogle Scholar
  8. 8.
    Shao R, Rockey DC: Effects of endothelins on hepatic stellate cell synthesis of endothelin-1 during hepatic wound healing. J Cell Physiol 2002, 191:342–350.PubMedCrossRefGoogle Scholar
  9. 9.
    Paradis V, Dargere D, Bonvoust F, et al.: Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002, 82:767–774.PubMedGoogle Scholar
  10. 10.
    Saxena NK, Ikeda K, Rockey DC, et al.: Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002, 35:762–771. One of two publications establishing the importance of leptin as a fibrogenic factor in liver injury. See annotation below.PubMedCrossRefGoogle Scholar
  11. 11.
    Ikejima K, Honda H, Yoshikawa M, et al.: Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001, 34:288–297. An additional reference establishing the importance of leptin as a fibrogenic factor in liver injury by demonstrating lack of fibrosis in animals genetically deficient in leptin. Both groups of authors describe a key potential mechanism to explain the association of NASH and liver fibrosis with obesity because obese patients typically have high leptin levels.PubMedCrossRefGoogle Scholar
  12. 12.
    Benyon D, Arthur MJP: Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis 2001, 21:373–384.PubMedCrossRefGoogle Scholar
  13. 13.
    Iredale JP: Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997, 29:43–54.PubMedCrossRefGoogle Scholar
  14. 14.
    Marra F, Romanelli RG, Pastacaldi S, et al.: Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999, 29:140–148.PubMedCrossRefGoogle Scholar
  15. 15.
    Ikeda K, Wakahara T, Wang YQ, et al.: In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999, 29:1760–1767.PubMedCrossRefGoogle Scholar
  16. 16.
    Bataller R, Brenner DA: Stellate cells as a target for treatment of liver fibrosis. Semin Liver Dis 2001, 21:437–452.PubMedCrossRefGoogle Scholar
  17. 17.
    Bonis PA, Friedman SL, Kaplan MM: Is liver fibrosis reversible? N Engl J Med 2001, 344:452–454.PubMedCrossRefGoogle Scholar
  18. 18.
    Kweon YO, Goodman ZD, Dienstag JL, et al.: Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001, 35:749–755. This study provides important evidence establishing that successful eradication of HBV by an antiviral agent (lamivudine) can diminish fibrosis in infected patients.PubMedCrossRefGoogle Scholar
  19. 19.
    Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303–1313. This landmark clinical study in a large number of patients establishes convincingly that even cirrhosis can be reversed upon clearance of HCV by IFN and ribavirin, lending optimism that cirrhosis need not necessarily lead to liver transplantation.PubMedCrossRefGoogle Scholar
  20. 20.
    Shiratori Y, Imazeki F, Moriyama M, et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517–524.PubMedGoogle Scholar
  21. 21.
    Cotler SJ, Jakate S, Jensen DM: Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001, 32:428–430.PubMedCrossRefGoogle Scholar
  22. 22.
    Pietrangelo A: Metals, oxidative stress, and hepatic fibrogenesis. Semin Liver Dis 1996, 16:13–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Houglum K, Venkataramani A, Lyche K, Chojkier M: A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997, 113:1069–1073.PubMedCrossRefGoogle Scholar
  24. 24.
    Houglum K, Ramm GA, Crawford DH, et al.: Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. Hepatology 1997, 26:605–610.PubMedCrossRefGoogle Scholar
  25. 25.
    Pietrangelo A, Borella F, Casalgrandi G, et al.: Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995, 109:1941–1949.PubMedCrossRefGoogle Scholar
  26. 26.
    Ferenci P, Dragosics B, Dittrich H, et al.: Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatology 1989, 9:105–110.CrossRefGoogle Scholar
  27. 27.
    Rockey DC, Chung JJ: Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Invest Med 1994, 42:660–670. This animal study provides a clear rationale for testing of IFN-γ in humans, an effort currently underway in a large controlled, randomized trial in patients with advanced HCV refractory to antiviral therapy.Google Scholar
  28. 28.
    King TE, Jr.: Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med 2000, 342:974–975.PubMedCrossRefGoogle Scholar
  29. 29.
    Marra F, Efsen E, Romanelli RG, et al.: Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000, 119:466–478.PubMedCrossRefGoogle Scholar
  30. 30.
    Kon K, Ikejima K, Hirose M, et al.: Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002, 291:55–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Galli A, Crabb DW, Ceni E, et al.: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002, 122:1924–1940.PubMedCrossRefGoogle Scholar
  32. 32.
    Caldwell SH, Hespenheide EE, Redick JA, et al.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:519–525. Although a small sample, this clinical study establishes the rationale for trials of PPAR-γ agonists (thiazolidinedione) in patients with NASH, justified in part by evidence in animals and cultured stellate cells that such compounds downregulate stellate cell activation.PubMedCrossRefGoogle Scholar
  33. 33.
    Frank S, Stallmeyer B, Kampfer H, et al.: Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 2000, 106:501–509.PubMedGoogle Scholar
  34. 34.
    Leclercq IA, Farrell GC, Schriemer R, Robertson GR: Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002, 37:206–213.PubMedCrossRefGoogle Scholar
  35. 35.
    Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042. This vital clinical study establishes the basis for highly targeted small molecule therapy based on a rational approach to neutralizing a key receptor that is pathogenic in leukemia. Similar approaches are being developed to treat hepatic fibrosis.PubMedCrossRefGoogle Scholar
  36. 36.
    Waltenberger J: Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation 1997, 96:4083–4094.PubMedGoogle Scholar
  37. 37.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052–1056.PubMedCrossRefGoogle Scholar
  38. 38.
    Kawada N, Seki S, Kuroki T, Kaneda K: ROCK inhibitor Y-27632 attenuates stellate cell contraction and portal pressure increase induced by endothelin-1. Biochem Biophys Res Commun 1999, 266:296–300.PubMedCrossRefGoogle Scholar
  39. 39.
    Tada S, Iwamoto H, Nakamuta M, et al.: A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol 2001, 34:529–536.PubMedCrossRefGoogle Scholar
  40. 40.
    George J, Roulot D, Koteliansky VE, Bissell DM: In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999, 96:12719–12724.PubMedCrossRefGoogle Scholar
  41. 41.
    Okuno M, Akita K, Moriwaki H, et al.: Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001, 120:1784–1800.PubMedCrossRefGoogle Scholar
  42. 42.
    Ueki T, Kaneda Y, Tsutsui H, et al.: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999, 5:226–230.PubMedCrossRefGoogle Scholar
  43. 43.
    Wang YJ, Wang SS, Bickel M, Bissell DM: Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathol 1998, 152:279–287.PubMedGoogle Scholar
  44. 44.
    Stefanovic B, Schnabl B, Brenner DA: Inhibition of collagen alpha1(I) expression by the 5’ stem-loop as a molecular decoy. J Biol Chem 2002, 277:18229–18237.PubMedCrossRefGoogle Scholar
  45. 45.
    Rockey DC, Chung JJ: Endothelin antagonism in experimental hepatic fibrosis: implications for endothelin in the pathogenesis of wound healing. J Clin Invest 1996, 98:1381–1388.PubMedGoogle Scholar
  46. 46.
    Yu Q, Shao R, Qian HS, et al.: Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000, 105:741–748.PubMedGoogle Scholar
  47. 47.
    Iredale JP, Benyon RC, Pickering J, et al.: Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998, 102:538–549. One of two studies that together provide a clear mechanistic rationale and proof of principle that apoptosis of stellate cells is a key event in resolution of liver fibrosis, and that accelerating this response can reduce fibrosis in an animal model. These studies provide strong incentive to develop similar approaches suitable for clinical trials.PubMedCrossRefGoogle Scholar
  48. 48.
    Wright MC, Issa R, Smart DE, et al.: Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001, 121:685–698. The second study supporting the role of apoptosis in the resolution of liver fibrosis.PubMedCrossRefGoogle Scholar
  49. 49.
    Salgado S, Garcia J, Vera J, et al.: Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000, 2:545–551.PubMedCrossRefGoogle Scholar
  50. 50.
    Beljaars L, Meijer DK, Poelstra K: Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002, 7:e214-e222.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Efsevia Albanis
  • Rifaat Safadi
  • Scott L. Friedman
    • 1
  1. 1.Division of Liver DiseasesMount Sinai School of MedicineNew YorkUSA

Personalised recommendations